Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note published on Tuesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Up 4.9 %

NASDAQ:EVOK opened at $4.58 on Tuesday. The firm has a fifty day simple moving average of $5.10 and a 200-day simple moving average of $5.50. Evoke Pharma has a 12 month low of $3.54 and a 12 month high of $17.40. The company has a market capitalization of $3.76 million, a P/E ratio of -0.41 and a beta of 0.36.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%. The business had revenue of $2.55 million for the quarter.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.